Berger et al67 conducted a 4-week naturalistic trial of desloratadine 5 mg/d in 331 subjects (66% female, 34% male; mean age, 32 years [range, 15–75 years]) with a ≥2-year history of moderate SAR and mild sea- sonal exacerbations of allergic asthma. Patients were moderately symptomatic at screening, with a rhinor- rhea score ≥2, TNSS ≥6, and TNNSS ≥5. Deslorata- dine was associated with significant reductions com- pared with placebo in morning/evening reflective nasal congestion scores, both over days 1 to 15 (−0.56 vs −0.38, respectively; P = 0.006) and days 1 to 29 (−0.64 vs −0.47; P = 0.014).